Paradigm Medical Communications, LLC

Paradigm Medical Communications, LLC Paradigm Medical Communications. n. Paradigm has been an ACCME-accredited provider of continuing medical education since 2007.

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. an exemplary, award-winning, medical education company that develops medical education activities using research-based needs assessments, which are innovative, well-designed, and well-executed, and that are continuously mon

itored to facilitate ongoing improvements. Paradigm has experience in developing and implementing CME programs in a wide variety of formats, including live events; print newsletters, monographs, and peer-reviewed journal supplements; electronic media (such as DVD); and web-based activities (including website design, development, and maintenance) as well as interdisciplinary web conferences, webinars, and podcasts. While Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians, we also have several long-standing collaborative relationships with the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC)-accredited providers that enable our activities to offer continuing education credit to the broadest range of identified target audiences. All activities developed and implemented by Paradigm Medical Communications are in adherence with the Essentials and Standards of the ACCME as well as guidelines established by the AMA, OIG, PhRMA, and FDA. Paradigm Medical Communications, LLC is dedicated to providing effective education based on the needs of the medical community. By working with thought leaders in various therapeutic areas, Paradigm Medical Communications is committed to developing impactful and innovative medical education activities designed to improve patient care strategies and patient quality of life by modifying physician behavior through the use of evidence-based, compelling, and applicable information. Cme-Accredited Provider
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. We completed our 4-year reaccreditation in 2009. Content Areas

The content areas of activities sponsored by our CME program include, but are not limited to, the following therapeutic areas: oncology, dermatology, diabetes, aesthetic medicine, hyponatremia, invasive fungal disease, infectious diseases, respiratory disease, cardiovascular disease, men's health, rheumatology, and thrombosis

Target Audience

Categories of learners targeted for education include:

US-based physicians and other health care professionals who participate in local, regional, or national activities
International health professionals who attend national conferences and/or access internet CME activities
Types of Activities

The types of activities developed include:

Live activities (symposia, local and regional meetings, hospital-based/Grand Rounds, hands-on and simulation workshops, satellite broadcasts)
Enduring materials (DVDs, peer-reviewed journal supplements, print monographs/newsletters)
Internet CME (websites, interactive cases, webinars, podcasts)
Paradigm develops activities designed to meet the preferences of our learners. This means that multiple formats are considered and implemented based on the needs of each target audience and educational intervention. Expected Results

The results expected from all educational activities are to demonstrate a change in the competence and/or performance of health care professionals and to ultimately impact patient outcomes. Continued program evaluation and assessment assists us in ensuring that activity content is relevant to learner's current educational gaps.

Complimentary CME! Have a look! Best practices imaging illustrates real-world data helping to fill in gaps in retinal di...
08/28/2026

Complimentary CME! Have a look! Best practices imaging illustrates real-world data helping to fill in gaps in retinal disease treatment related to agent selection and dosing interval decisions.

Link in bio or Scan QR code
https://paradigmmed.org/1463SM

COMPLIMENTARY CME!  View an interactive infographic highlighting the pathophysiology targeted by emerging agents for Sjö...
08/27/2026

COMPLIMENTARY CME! View an interactive infographic highlighting the pathophysiology targeted by emerging agents for Sjögren’s disease with the current data. Faculty discussion will bring the data into context for potential clinical use.

Link in bio or Scan QR code
Https://paradigmmed.org/1396SM

COMPLIMENTARY CME! View Now!Experts describe best practices for allergists to apply shared decision-making in the manage...
08/26/2026

COMPLIMENTARY CME! View Now!
Experts describe best practices for allergists to apply shared decision-making in the management of food allergy.

Link in Bio or scan QR code
Https://paradigmmed.org/1436SM

COMPLIMENTARY CME! These CME activities feature our expert faculty providing insights on guideline-based care, the use o...
08/25/2026

COMPLIMENTARY CME! These CME activities feature our expert faculty providing insights on guideline-based care, the use of clinical trial data to explore new glaucoma treatments, and how to tailor glaucoma care to individual patients.

Link in Bio or Scan QR code
https://paradigmmed.org/1404LP

08/24/2026

FREE CME! The treatment of nonrenal systemic lupus erythematosus (SLE) is expected to evolve as new agents emerge for treatment. How do these agents work? What are the efficacy and safety data? And how should these be incorporated into guideline-aligned treatment of SLE? Our faculty discusses these in the context of 2 case examples illustrating their thought process in selecting treatment for SLE.

Link in bio or Scan QR code
https://paradigmmed.org/1477SM

08/24/2026

Free CME! Two goals in treatment of neovascular age-related macular degeneration (nAMD) compete. Resolution of macular fluid competes with reducing treatment burden. More anti-vascular endothelial growth factor (VEGF) injections lead to better outcomes. More anti-VEGF injections also lead to greater treatment burden. With the chronic nature of nAMD, many patients are not able to sustain the treatment burden and reduce clinic visits, resulting in suboptimal outcomes. Join retina experts as they discuss how they balance these competing patient needs. Treatment options for nAMD continue to increase. Can these new options bring balance to the competing treatment goals?

Link in bio or Scan QR code
https://paradigmmed.org/1416-5SM

COMPLIMENTARY CME! View this interactive match game that compares trial versus real-world data for second-generation ret...
08/21/2026

COMPLIMENTARY CME! View this interactive match game that compares trial versus real-world data for second-generation retinal therapies in patients with DME or nAMD.

Link in Bio or scan QR code
https://paradigmmed.org/1464SM

FREE CME! Join host Dr Sridhar and guests Drs Ip and Bakri for a podcast highlighting the challenges in care of patients...
08/20/2026

FREE CME! Join host Dr Sridhar and guests Drs Ip and Bakri for a podcast highlighting the challenges in care of patients with macular edema secondary to retinal vein occlusion (RVO). With the American Academy of Ophthalmology RVO Preferred Practice Pattern as a guide, the faculty consider the current approach to treatment using anti-vascular endothelial growth factor (VEGF) agents and factors that may suggest a need for more intensive, long-term treatment. The anti-VEGF agents have been standard of care for over a decade; however, many patients need frequent injections to be effective. The anti-VEGF agents faricimab and aflibercept 8 mg have shown noninferior efficacy and greater durability in pivotal clinical trials at reducing patient treatment burden.

Link in bio or Scan QR code
Https://paradigmmed.org/1403-1INS

FEATURED FREE CME! View now! As late-phase trials of anti-TLIA therapies for IBD progress, clinicians need to stay infor...
08/19/2026

FEATURED FREE CME! View now! As late-phase trials of anti-TLIA therapies for IBD progress, clinicians need to stay informed on this novel mechanism of action and its potential role in personalized treatment strategies. Anti-TLIA therapy could redefine the therapeutic landscape. Are you ready to integrate the next breakthrough?

Link in Bio or Scan QR code
Https://paradigmmed.org/1434INS

FREE CME! Effective management of diabetic retinopathy (DR) and diabetic macular edema (DME) requires sorting through an...
08/17/2026

FREE CME! Effective management of diabetic retinopathy (DR) and diabetic macular edema (DME) requires sorting through anti-vascular endothelial growth factor (VEGF) options to initiate an agent when needed or to switch therapies when treatment fails. Also key to successful management of DR/DME is staying current on the approaches to monitor disease activity using optical coherence tomography biomarkers and response prediction. This is particularly important as the new anti-VEGF agents aflibercept 8 mg and farcimab allow for longer dosing intervals. Join Yasha Modi, MD as he dives into the details of managing patients with DR/DME using a treat-and-extend approach.

Link in bio or Scan QR code
https://paradigmmed.org/1415-5SM

Address

523 Route 303
Orangeburg, NY
10962

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Alerts

Be the first to know and let us send you an email when Paradigm Medical Communications, LLC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category